Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

BC Ferries remains indispensable, but it cannot and should not be the only player shaping the future of coastal mobility.

Omeros Corporation (NASDAQ: OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

The City of Hazleton is launching a new camera system they say will increase safety in the city and complement the existing ...

The residential battery energy storage system is the first non-vehicle product by Ola Electric. This new solution will ...

India’s new envoy to Canada rejected Foreign Minister Anita Anand’s claim that New Delhi has agreed to restore Canada’s full complement of diplomats. Indian High ...

Learn about the innovative plug flow technology that could make rain a major renewable energy source for cities worldwide.

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...